Funded Biotechnology Startups in Barcelona
Barcelona's biotechnology sector has generated consistent funding activity from early 2021 through October 2025 across the 33 rounds shown here.
Barcelona's biotechnology sector has generated consistent funding activity from early 2021 through October 2025 across the 33 rounds shown here. The standout raise is Splice Bio's $135M Series B in June 2025 — the largest disclosed round in the dataset by a wide margin. Atrys Health's $76M post-IPO equity close in June 2022 ranks second. Ten of the 33 rounds closed in 2025 alone, a pace that includes two Series B deals, a pair of July 2025 closes (Minoryx Therapeutics at $31M, Oryzon Genomics at $16M), and Integra Therapeutics' $13M seed in September 2025.
Therapeutics-focused companies dominate by naming convention — Ona, Integra, Minoryx, Connecta, ADmit, Oniria, Nuage, Kintsugi, and Aelix Therapeutics all appear in the list. Seed rounds are the most frequent stage type, though disclosed amounts range widely, from Rethink Medical's $10K raise in October 2023 to Splice Bio's nine-figure close. Two rounds — IMIDomics and Nuage Therapeutics — list undisclosed amounts.
Most recent rounds
33 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this Barcelona biotech dataset?
Splice Bio leads with a $135M Series B closed in June 2025, the largest single raise in the dataset. Atrys Health's $76M post-IPO equity round in June 2022 ranks second, followed by Minoryx Therapeutics ($31M, July 2025), Seqera ($26M Series B, May 2025), and Aortyx ($16M Series A, June 2025).
How does 2025 funding activity compare to prior years in this cohort?
Ten of the 33 rounds closed in 2025, matching 2023 for the highest annual count in the dataset. The 2025 closes include the largest raise shown (Splice Bio, $135M), two mid-range Series B deals, and four rounds in the $12M–$31M range. By contrast, 2024 and 2022 each account for five rounds, and 2021 for three.
What funding stages are most common among these companies?
Seed is the most frequently labeled stage, covering at least 11 companies including Integra Therapeutics ($13M), OneChain Immunotherapeutics ($7M), Connecta Therapeutics ($3M), and Zymvol Biomodeling ($3M). A large share of rounds carry a 'Series Unknown' or 'Venture – Series Unknown' label, indicating informally structured or undisclosed stage raises.
Are there any post-IPO or late-stage companies in this set?
Atrys Health is the only post-IPO company shown, raising $76M in a post-IPO equity round in June 2022. Splice Bio and Seqera represent the most advanced pre-exit positions, both closing Series B rounds in 2025 at $135M and $26M respectively.
How wide is the spread of disclosed round sizes in this cohort?
Disclosed amounts range from Rethink Medical's $10K raise in October 2023 to Splice Bio's $135M Series B in June 2025. Most rounds cluster below $15M, with Bioinspired Materials ($840K, May 2025) and Libre Foods ($370K, December 2023) near the lower bound. Two rounds — IMIDomics and Nuage Therapeutics — list undisclosed amounts.
How prominent are therapeutics-focused companies relative to the broader cohort?
At least nine companies carry the '-therapeutics' suffix — Ona, Integra, Minoryx, Connecta, ADmit, Oniria, Nuage, Kintsugi, and Aelix Therapeutics — indicating a strong drug-development orientation in the Barcelona cohort. Other companies such as INBRAIN Neuroelectronics, Gate2Brain, Pulmobiotics, Oryzon Genomics, and Seqera point to adjacent focus areas including neurotech, genomics, and computational biology.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.